Weiguo Ye Biography and Net Worth

COO of Gyre Therapeutics

Mr. Weiguo Ye is Gyre Therapeutics’ Chief Operating Officer. Mr. Ye has over 20 years of experience in the pharmaceutical industry.

Mr. Ye joined Beijing Continent Pharmaceuticals (“BC”) in December 2016 as a sales director and further served as the vice president from September 2017 to May 2018 and the executive vice president since May 2018 and was later promoted to be the chief operating officer in January 2021. He is primarily responsible for overall management of marketing business and daily operation of BC. In April 2023, Mr. Ye served as a Director and the President of BC, and is primarily responsible for the overall management and operation of BC. Prior to joining BC, Mr. Ye served as the marketing vice president of Hubei Monyan Pharmaceuticals Co., Ltd., the grand area manager and national sales director of Jiangsu Simcere Pharmaceutical Co., Ltd., and the regional sales manager of Shanghai Roche Pharmaceutical Ltd.

Mr. Ye obtained his undergraduate diploma in applied pharmacy through online learning from Peking University in the PRC. He further obtained his executive master of business administration degree (EMBA) from China Europe International Business School. In May 2021, Mr. Ye was recognized as a leading talent of “Wutong Project” of Shunyi District.

What is Weiguo Ye's net worth?: The estimated net worth of Weiguo Ye is at least $4.22 million as of May 20th, 2026. Mr. Ye owns 700,000 shares of Gyre Therapeutics stock worth more than $4,216,800 as of June 10th. This net worth estimate does not reflect any other assets that Mr. Ye may own. Learn More about Weiguo Ye's net worth.
How do I contact Weiguo Ye?: The corporate mailing address for Mr. Ye and other Gyre Therapeutics executives is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. Gyre Therapeutics can also be reached via phone at (619) 949-3681 and via email at [email protected]. Learn More on Weiguo Ye's contact information.
Has Weiguo Ye been buying or selling shares of Gyre Therapeutics?: During the last ninety days, Weiguo Ye has sold $136,653.00 in shares of Gyre Therapeutics stock. Most recently, Weiguo Ye sold 12,820 shares of the business's stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.15, for a transaction totalling $78,843.00. Following the completion of the sale, the chief operating officer now directly owns 700,000 shares of the company's stock, valued at $4,305,000. Learn More on Weiguo Ye's trading history.
Who are Gyre Therapeutics' active insiders?: Gyre Therapeutics' insider roster includes Ying Luo (CEO), Songjiang Ma (President), Nassim Usman (Director), and Weiguo Ye (COO). Learn More on Gyre Therapeutics' active insiders.
Are insiders buying or selling shares of Gyre Therapeutics?: During the last year, insiders at the sold shares 4 times. They sold a total of 32,535 shares worth more than $219,580.23. The most recent insider tranaction occured on May, 21st when COO Weiguo Ye sold 12,820 shares worth more than $78,843.00. Insiders at Gyre Therapeutics own 9.5% of the company. Learn More about insider trades at Gyre Therapeutics.
Information on this page was last updated on 5/21/2026.

Weiguo Ye Insider Trading History at Gyre Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/21/2026	Sell	12,820	$6.15	$78,843.00	700,000
5/20/2026	Sell	9,400	$6.15	$57,810.00	700,000

Weiguo Ye Buying and Selling Activity at Gyre Therapeutics

Gyre Therapeutics Company Overview

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Today's Range

Now: $6.03

$6.00

$6.34

50 Day Range

MA: $6.95

$5.56

$8.10

2 Week Range

Now: $6.03

$5.44

$9.42

Volume

42,297 shs

Average Volume

91,429 shs

Market Capitalization

$584.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9